Wednesday, 14 October 2026European Markets

ZAPTEC Stock Was 17.05% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with ZAPTEC (ZAP.OL) jumping 17.05% to kr12.36 on Wednesday while Oslo Børs Benchmark Index_GI fell 0.19% to kr1,425.94.

ZAPTEC's last close was kr10.56, 67.9% below its 52-week high of kr32.90.

About ZAPTEC

Zaptec ASA engages in the development and sale of chargers, charging systems, and services for electric car charging in Norway, Sweden, Switzerland, Denmark, Iceland, rest of Europe, and internationally. It offers Zaptec Go and Zaptec Pro alternating current walls charging station for indoor and outdoor use; Zaptec Portal, a cloud platform that monitors, balances, and optimizes the load between charging stations, while displaying real-time power usage; and Zaptec Sense for automatically adjusting the charging speed in the buildings. The company also offers accessories, including covers, charging cables, cable holders, RFID tags, and load balancers. Zaptec ASA was incorporated in 2012 and is headquartered in Stavanger, Norway.

Earnings Per Share

As for profitability, ZAPTEC has a trailing twelve months EPS of kr0.22.

PE Ratio

ZAPTEC has a trailing twelve months price to earnings ratio of 56.18. Meaning, the purchaser of the share is investing kr56.18 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.79%.

Yearly Top and Bottom Value

ZAPTEC's stock is valued at kr12.36 at 22:31 EST, way below its 52-week high of kr32.90 and way higher than its 52-week low of kr11.01.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 111.1% and a negative 89.7%, respectively.

More news about ZAPTEC (ZAP.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com